Background Multiple sclerosis (MS) is a chronic neurological disorder, which can lead to a wide range of disabling symptoms. The condition has a significant negative impact on health-related quality of life, and the economic cost of the disease is substantial. Decision-making regarding treatments for MS, and particularly disease-modifying interventions, has been hampered by limitations in the data and evaluative framework for assessing their cost effectiveness. Whilst attention has been drawn to these weaknesses, the scope and extent of the challenges in this area have not been fully set out to date. Aims The aims of this review were to identify all published economic evaluations of MS treatments in order to provide a statement on the scope and characteristics of the cost-effectiveness literature in the area of MS and to provide a basis on which to suggest practical recommendations for future research to aid decision-making. Method A systematic search was undertaken to identify economic evaluations of treatments for people with MS published in English up to December 2011. Included studies were reviewed to provide a comprehensive description of the characteristics of the currently applied framework for cost effectiveness in MS, with the following key methodological components considered: methods for estimating disease progression, the impact of treatment and health outcomes and costs associated with MS. Results Thirty-seven papers were identified. Most studies (n = 32) were model-based evaluations of disease-modifying drugs. All models used disability stages defined by the Expanded Disability Status Scale (EDSS) to characterise disease progression, and the impact of treatment was based on data from clinical trials and epidemiological cohorts. Outcomes were primarily based on quality-adjusted lifeyears (n = 22) and/or related to relapse (n = 14). Estimates for health state utility values (HSUVs), costs and the impact of treatment on the course of MS varied considerably between studies, depending on the data sources used and the methods used to incorporate data into models. The scope of the studies was narrow, with a sparsity of economic evaluations of symptomatic and/or non-pharmacological interventions; exclusion of direct non-medical, indirect and informal care costs from analyses; and a narrow view of the potential impact of treatment, concentrating on disability, according to the EDSS, and relapses. In addition, there were issues concerning how to capture losses in HSUVs due to relapses in a way that reflects their salience to people with MS, the wide variation in costs and outcomes from different sources and from potentially unrepresentative samples and modelling disease progression from natural history data from over 30 years ago. Conclusion There are many complexities for those designing and reporting cost-effectiveness studies of treatments for MS. Analysts, and ultimately decision makers, face multiple data and methodological challenges. Policy makers, technology developers, clinicians, patients and researchers need to acknowledge and address these challenges and to consider recommendations that will improve the current scenario. There is a need for further research that can constructively inform decision-making regarding the funding of treatments for MS.
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Key points for decision makers
• Much of the information available about the costs and benefits of treatments for MS has limitations. This can contribute to uncertainty about the cost effectiveness of interventions for MS and should be clearly tested in the process of weighing up the value for money of MS treatments.
• MS has a wide-reaching impact on people's quality of life and the health and other care services that they need. Studies that look at the cost effectiveness of interventions for MS need to take this broad view if they are to capture the true costs and effects of treatments.
• Data from 30 years ago has often been used when considering the cost effectiveness of MS treatments. Current data are sorely needed, which are as widely relevant as possible to people with MS. Policy makers, technology developers, clinicians, patients and researchers all have a role to play in calling for such research, which will help to make better informed decisions about funding treatments for MS.
Introduction
Multiple sclerosis (MS) is a chronic disabling neurological disorder, which leads to limitations in mobility, fatigue, spasticity, pain, urinary dysfunction, gastrointestinal dysfunction, and vision, speech and psychological problems, all of which negatively affect the health-related quality of life (HRQL) of people with MS [1] . The economic cost of MS is substantial given the long duration of the illness, the increasing need for assistance in everyday activities and reduced economic activity in patients of working age due to the peak age of onset at age 30 years [2, 3] . Given the limited therapeutic options available, the search for effective treatments in MS is a priority. Immunomodulatory or disease-modifying drugs (DMDs) have been found to be effective in reducing the risk of relapse (episodic attacks followed by periods of remission); however, their impact on delaying or preventing disease progression is not proven, as measured by changes in long-term disability [4, 5] .
The high costs associated with modern biological agents such as DMDs have presented an ongoing challenge for health-care funders facing competing demands who need to understand the relative costs and benefits (cost effectiveness) of new and expensive therapies compared to existing interventions. In MS this task is complicated by the long-term and unpredictable nature of MS and its multisector economic impact, as well as clinical and research debates about the methods used to measure MS progression and the long term effectiveness of treatments.
Data on the costs of care and the HRQL (particularly in the form of quality-adjusted life-years, or QALYs) of people with MS have been reported as sparse and/or methodologically compromised (e.g. Boggild et al. [5] , Kobelt et al. [6] and Orme et al. [7] ), and weaknesses in the evaluative framework for assessing the cost effectiveness of treatments for MS have been repeatedly highlighted in the research literature (e.g. Chilcott et al. [8] , Naci et al. [9] and Phillips and Humphreys [10] ). In turn, these limitations in the assessment framework have hampered decisionmaking regarding the funding of treatments for MS. For example, consideration of the cost effectiveness of the DMDs beta interferon, glatiramer acetate [11] and natalizumab [12] by the National Institute for Health and Clinical Excellence (NICE) in the UK has been clouded by methodological difficulties with the economic models. In the absence of good quality data, the controversial MS Risk Sharing Scheme (RSS) was established in the UK [11] against a backdrop of considerable media attention. The MS RSS remains controversial [13] and 10 years on recent NICE guidance regarding the funding of another DMD, fingolimod [14] , has highlighted still multiple problems with the appraisal framework for MS treatments.
Previous reviews of the cost effectiveness of MS treatments [10, [15] [16] [17] [18] [19] have been limited to descriptive and critical summaries of small numbers of published costeffectiveness analyses (CEAs) and their findings. Apart from some suggestions for the need for more trial-based data and a more standardised approach to CEAs of treatments for MS, the published reviews do not comment in any detail on the methodological challenges in the current CEA framework. The current review aims to add to this somewhat fragmentary and undeveloped literature through a comprehensive and systematic search of all economic evaluations of MS treatments published to date, with a specific focus on considering the framework used to assess the cost effectiveness of interventions for MS. There is clearly a need to capture the range and variety of approaches that have been taken and to draw on these in giving practical recommendations for future research that will aid decision-making in this field.
Methods
A systematic search was undertaken to identify economic evaluations of treatments for people with MS published in English up to December 2011. It was not the intention of this review to provide a summary indicator of cost effectiveness or to present detailed summaries of individual economic evaluations with study-specific critical appraisals of methodological strengths and weaknesses. The aim here was to provide a commentary on the scope and characteristics of the cost-effectiveness literature in MS.
An example of the search terms used for the MEDLINE database appears in the Appendix. The search terms were adapted as necessary to conduct searches in EMBASE, the CEA registry, NHS Economic Evaluation Database, PsycINFO, ISI Web of Science and EconLit. The initial search produced 1,078 citations, which were reviewed separately by two reviewers to identify relevant papers. Fifty-seven citations were identified as potentially relevant and complete references for these were reviewed to identify economic evaluations for final inclusion. Reviews, cost studies without comparators, methodological papers, outcome studies, pharmacological models, clinical decision models, and epidemiological or statistical models were excluded. Reference lists and citations of retrieved articles and existing reviews were further checked to ensure that no eligible studies had been missed.
The main methodological approaches taken by the included studies are outlined in the Results section followed by a detailed commentary in the Discussion including recommendations for research and decision-making.
Results

Summary of the Included Studies
The literature review identified 37 economic evaluations (Fig. 1) . The characteristics of these evaluations are summarised in Table 1 , with further detail in the online Table. The studies were set in either European (n = 19) or North American (n = 18) health-care systems. Most studies (n = 32) were model-based evaluations of DMDs. These included natalizumab [20] [21] [22] [23] [24] [25] , glatiramer [8, 22, 23, [26] [27] [28] [29] [30] [31] [32] [33] [34] , interferon-b-1a [8, 20, 21, 23, 24, [26] [27] [28] [29] [30] [31] [32] [33] [35] [36] [37] , interferon-b-1b [8, 20, 21, 23, 24, 26-30, 32, 33, 38-48] , mitoxantrone [38, 49] , fingolimod [25] , stem cell transplantation [49] and hypothetical disease-modifying interventions [50] . Two studies reported CEAs of supportive care programmes conducted alongside randomised clinical trials [51, 52] , and three studies reported the costs and outcomes of alternative treatment approaches based on medical insurance claims data [53] [54] [55] . Most studies adopted a third party payer perspective (n = 18), such as medical insurance plans and national health-care systems, eight took a societal perceptive and ten presented results for both perspectives.
Modelling Methods
Almost all the studies identified in this review were modelbased evaluations (n = 32). The course of MS is variable [4] , and the natural history of the condition commonly dictates the use of long-term disease progression models in CEA studies. Most patients (85 %) initially experience a 'relapsing-remitting' disease course (RRMS), characterised by recurrent symptomatic attacks (relapses) followed by periods of complete or almost complete recovery (remissions). Half go on to develop the 'secondary progressive' form of the disease (SPMS) marked by a steady progression of symptoms without periods of remission. A smaller proportion of mainly older patients (15 %) initially present with a 'primary progressive' pattern where the symptoms progress from onset without clearly defined remissions or relapses (PPMS). Disease progression was modelled in most studies according to the Expanded Disability Status Scale (EDSS) [56] , a 10-point measure of disability in MS with increments of 0.5 and 1.0 points, which increasingly focuses on mobility impairment as the disease progresses. Disease progression or natural history, using EDSS, was simulated using data from untreated MS patients enrolled in RCT placebo groups [20, 21, 23, 27, 28, 30, 34, 35, 37-40, 42, 43, 45, 46] (n = 16), the London, Ontario cohort data set [8, 22, 24, 29, 32-34, 36, 39, 41, 42, 48] (n = 12), other epidemiological cohorts [22, 26, 28, 32, 33, 35, 44] (n = 7), MS patient registries [24, 49, 50] (n = 3) or commercial data sources [8, 31, 43] (n = 3).
Most models used Markov transition states [8, 22-24, 28, 29, 32, 33, 36, 38, 39, 41-43, 46, 48-50] (n = 18), with other model types described as mathematical models [26, 44] (n = 3), spreadsheet models [27, 30] (n = 2), budget impact analysis models [20, 21] (n = 2), epidemiological models [40, 44] (n = 2), decision analytic models [25, 34, 47] (n = 3), discrete event simulation [35] (n = 1), and time series regression [37] (n = 1). The impact of treatment on disease progression was based on observed differences between treatment and placebo groups in RCTs [20, 21, 23, 25, 27, 28, 30, 31, 34, 35, 37-42, 45, 46] (n = 18) or through the application of treatment effects observed in RCTs [8, 22, 24, 26, 29, 32, 33, 36, 43, 44, 48] when combined with observational data (n = 11) or patient registries [47, 49, 50] (n = 3). Statistical methods or assumptions were used to extrapolate the observed natural history and treatment data, although some studies limited their time horizon to the available data without extrapolation [20, 21, 27, 30, 31, 34, 39, 41, 47] (n = 8).
Outcomes
The majority of studies ascribed health state utility values (HSUVs) to EDSS states, with HSUVs also being applied to relapse events. These HSUVs at different stages of disease progression, and in relation to relapses, were then used to estimate quality-adjusted life years (QALYs) as the primary endpoint in the economic analyses. Twenty-two of the 37 papers used QALYs as an outcome measure in order to estimate the cost-per-QALY of the intervention. In addition, eight studies [20, 21, 25, 27, 28, 30, 31, 35] used the frequency and/or severity of relapses as the primary outcome, and seven studies used other outcomes including patient reported outcomes from RCTs regarding functioning and symptoms [51, 52] , MS-related hospitalisations from medical insurance claims [53] [54] [55] and projected changes in EDSS scores [37, 44] .
The HSUVs that were used as QALY weights were taken from 12 source studies [2, 7, 26, 47, 50, [57] [58] [59] [60] [61] [62] [63] . All but one of these source studies [2, 7, 26, 47, 50, 57, [59] [60] [61] [62] [63] used generic health status measures that were completed by people with MS in surveys and/or trials. The health states described by these measures were thereafter assigned HSUVs from general population samples. The EQ-5D [64, 65] was the most commonly used generic measure (8/12), although other measures (the SF-6D [66, 67] and the HUI3 [68] ) and methods (standard gamble) of health state valuation were also used. The empirical data used to estimate QALYs were characterised by widely varied HSUVs, some significant differences in how HSUVs were calculated and potentially serious methodological limitations, such as very low response rates with the probability of unrepresentative samples of people with MS. There was also substantial variation in the relapse-related HSUV decrements used in the cost-utility analyses.
Costs
The included studies used cost data from cohort studies, medical insurance claims databases, cost studies, patient surveys, national tariffs and assumptions based on clinical opinion or other treatment guidelines. Thirteen studies [20, 21, [36, 40] and lost leisure hours [36, 42, 45] . The human capital approach [22-24, 26, 32, 36, 38-43, 46, 50] or the friction cost method [28, 45] were used to value indirect costs, usually as a proportion of genderand age-specific average wage rates. Informal costs of unpaid caregiver time were considered in 18 of the evaluations [22, 24, 26, 28, 32-34, 36, 38-43, 45, 46, 50, 51] and were valued as either a proportion of gender-and age-specific average wage rates [22, 24, 32, 36, 38, 39, 41, 43, 46, 50] or at replacement cost based on home care worker rates [34, 40, 42, 45, 51] . The inclusion of costs associated with adaptations and equipment was specifically noted in 11 studies [22, 24, 28, 32, 39-41, 43, 45, 46, 50] .
Discussion
This review of the methodology used for assessing the cost-effectiveness of treatments for MS describes limitations with the CEA framework commonly used and the data available. The following discussion focuses on the methods used in the studies to model disease progression in the context of CEA and to identify and value outcomes and resource use. It also considers the scope of economic evaluations of treatments for MS. 
Disease Progression
The health states in models used to characterise MS progression in the included studies were all defined using EDSS disability stages, with or without relapses. Although the EDSS is widely used in practice and clinical trials, it suffers from poor inter-(and within-) rater reliability and random variation and is widely acknowledged to have limitations [69, 70] . MS disease progression tends not to occur in a predictable linear fashion through all EDSS states, and HSUVs and costs may not be linearly related to EDSS stages [2, 7, 61, 71] . Therefore, change from one EDSS point to the next cannot be assumed to be equivalent across the range of the measure. As such, using the EDSS as an interval variable in statistical models of disease progression (e.g. regression analyses), and statistical models to estimate HSUVs, may contribute to bias in assessing cost-effectiveness. Most studies used placebo group data to simulate natural disease progression; however, the value of placebo data is limited by relatively short observation periods, the often limited generalisability of clinical trial participants and questions about which placebo data to use when comparing more than one treatment [24] . For these reasons models also used longer term natural history studies to predict EDSS progression. However, the two most frequently cited natural history studies [72, 73] were based on data collected between 1950 and 1984 and therefore may not reflect subsequent advances in the management of MS. Furthermore, there have been concerns that EDSS progression in untreated MS patients may be much slower than previously estimated. For example, a Canadian cohort based on 2,319 patients estimated median time to EDSS 6 was 27.9 years [74] , almost twice as long as the 15 years estimated in the historic London, Ontario cohort [72, 73] used in multiple analyses. Such differences in progression may have a significant impact on the projected benefits of treatments.
A number of studies have characterised disease progression based on relapse events. However, relapse events have been considered difficult to define both clinically and for the purposes of trial and economic analyses [75] , and some authors acknowledged a tendency to focus on more severe relapses requiring hospitalisation [48] . In CEA studies, although a reduction in relapse event rate may have a broader significance, the impact of events (reduction in event rate) is largely dependent on assumptions about their duration and severity, with most relapse events being rated as not severe, and most events being regarded as short-term (less than 2 weeks) [76] . Therefore, the relative infrequency of relapses, and their often short-term nature, together with a relatively modest effect on relapse rate of many DMDs, can result in relapse events having little impact in terms of QALYs modelled over the longer term course of this disease. As such, the effect of relapses in economic models may not reflect their salience for people with MS [77] .
Health-Related Quality of Life and Health State Utility Values
As described above, the impact of MS progression on HRQL has commonly been captured in CEA studies through the use of health state utility values for EDSS states and relapse events, and subsequent estimation of QALYs associated with treatments (and comparators) for MS. However, the empirical data used to estimate HSUVs for EDSS states and impact of relapses has some [7] ). The differing impact of relapse events on QALY estimates could, in part, be attributed, to the different methods used in the source studies to derive them [2, 26, 33, 47, 62] . For example, asking people with MS to rate their health status when they have had a relapse in the preceding 3 months [2] generates different answers than asking people to rate their health status whilst currently experiencing a relapse [62] . This said, the HSUV decrements provided for individuals currently in a relapse state also varied considerably (e.g. Noyes et al. [26] , Parkin et al. [62, 78] ).
This uncertainty regarding the reliability and precision of QALY weights used in cost-effectiveness analyses can be dealt with statistically. Deterministic and probabilistic sensitivity analyses (PSAs) can be used, whereby the effect of altering the HSUVs is explored. However, if not approached thoughtfully, sensitivity analyses may take little account of the actual wide variation found in reported HSUVs. It may be more appropriate to conduct scenario sensitivity analyses, using different sources of HSUVs to determine their differential effect on cost-effectiveness findings.
Resource Use and Costs Associated with MS
Cost-of-illness studies in MS [3, 79] have shown that the main drivers of costs in MS in most countries have been lost productivity, social care, informal care and expenditures on adaptations and equipment. However, half of the published economic evaluations identified in this review specifically excluded direct non-medical costs (i.e. costs of social care), indirect costs and costs associated with unpaid informal care, and less than one third explicitly recognised costs of adaptations and equipment. Thus, half of the published economic evaluations may have underestimated the full economic impact of interventions for MS. The main reason for this omission was that many evaluations were commissioned or supported by third party payers such as medical insurance providers and national health-care systems and therefore were limited to the health-care payer perspective. It has been argued that policy makers should be aware of all the costs and benefits associated with interventions particularly where the external costs and benefits for certain disease types or patient groups may be substantially greater than the health foregone elsewhere in the health-care system [80] . The incorporation of indirect costs and the costs of informal care into economic evaluations, however, can prove problematic. The human capital approach was the most common method of valuing lost productivity, through applying various wage rates to work, leisure and education hours lost due to absenteeism, early retirement, unemployment or, in some cases, hours of unpaid informal care. However, it has been argued that the human capital approach may overstate the opportunity cost of lost production compared to the friction cost method, which assumes such losses are limited when workers are eventually replaced [81] . Decision makers should be aware of the different methods used to measure and value costs in evaluations and judge whether these are relevant to their own decision-making context.
Scope of CEA Framework for MS
The current CEA framework for evaluating treatments for MS takes a narrow view of the impact of MS, focussing on disability as defined by the EDSS and relapse and potentially missing many outcomes important from the patient perspective. Given the significant impact of MS on HRQL, across a wide range of symptoms, and the importance of non-pharmacological treatments for people with MS, there was a sparsity of CEA research on symptomatic and/or non-pharmacological interventions; rather, the literature is characterised by economic models of the cost effectiveness of DMDs. This focus is understandable given that the majority of published economic models were typically sponsored by drug manufacturers. However, this may have overshadowed the economic benefits of drug and non-drug interventions targeted towards symptoms of MS shown to have an impact on HRQL such as spasticity, pain and fatigue, as well as other mainstays of treatment including psychotherapy and rehabilitation. Other reviews have found that in some cases particular symptoms have been associated with increased costs including fatigue, hand function, cognitive impairment, optical neuritis and pain [1] . Indeed, it could be argued that improvements in the symptomatic management of MS have significantly improved patient quality of life since the first cohort studies were conducted in the 1950s.
Conclusion and Implications
This review, based on a systematic search for economic evaluations, provides a summary of the current state of the literature regarding the CEA framework used for assessing interventions for MS. It reviews the body of literature as a whole to highlight methodological and data issues presenting as potential limitations in the current CEA framework for MS and to suggest ways to address them. The review does not aim to consider or aggregate the relative cost effectiveness of different types of interventions for MS. Such an undertaking has been covered in part by others [10, [15] [16] [17] [18] [19] , and has been argued to have limited value [82] .
Limitations in the CEA framework commonly applied in MS are largely attributable to frailties in the methods available to measure health outcomes and in the evidencebase used to assess the effectiveness of treatments for MS. There is a clear need for further research to provide high quality, valid data on outcomes, effectiveness, disease progression and costs in the area of MS, which may then be used in economic evaluations. Such research and data are required in a number of areas. However, whilst recognising gaps in the available evidence and concerns regarding the quality of the evidence, there are aspects of current practice in CEAs of MS treatments that are worthy of comment.
The mixture of approaches used to calculate and report health state utility values of MS health states identified in this review suggests the need for some consensus and consistency. Indeed, Saramago et al. [83] have recently highlighted the need for careful consideration of the sources of outcome and cost data that are used in cost-effectiveness models. Data on costs and outcomes for MS identified in the present review were very varied and led to much uncertainty. Potential issues with the reliability of parameter values should be explored thoughtfully in uncertainty analyses. Relatively simple tests of sensitivity such as scenario analyses that reflect the actual variation in HSUVs, rather than letting variation be statistically driven, could be employed here. As Ara et al. [84] reflect, uncertainty in HSUVs in decision-analytic models is currently generally poorly reported and rarely fully characterised.
Multiple sclerosis has a major impact on many areas of people's lives [1] . This broad influence has not been reflected in the perspective taken in many economic evaluations of treatments for MS. While recognising the technical difficulties in measuring and valuing informal care costs, other non-medical costs and indirect costs, a greater consideration of the economic impact of MS from the patient and societal perspective is warranted to reflect the full economic burden of MS and the potential impact of treatment. In addition, the variety of treatments considered in cost-effectiveness analyses has been narrow; there is a clear need for economic evaluations of symptomatic and non-pharmaceutical interventions for MS. The perspective and focus of cost-effectiveness analyses is often predetermined and beyond the remit of the analyst, i.e. health policy makers and pharmaceutical companies often set the context and the questions to be answered. Discussion and pressure from patient advocacy groups, clinicians and researchers alike may help to widen the lens of economic evaluations of treatments for MS.
Use of the EDSS as the main outcome measure in costeffectiveness analyses also takes a narrow view of the impact of MS on people's lives. Currently, the EDSS is the dominant instrument used in MS clinical and research practice. However, its limitations imply the need to develop viable alternative measures for staging MS disease progression. Such alternatives, as well as being appropriate for use in economic evaluations, should capture outcomes more broadly, have sound psychometric properties, and be acceptable to clinicians and for licensing purposes. In addition to devising a valid approach (or approaches) for capturing the effects of disease progression on HRQL, research is required to investigate the interdependent effects of disease progression and relapses on HSUVs. This is needed if decision makers are to more completely understand the value of interventions that impact on both these aspects of MS.
People with relapsing-remitting MS live with little knowledge of if and when a next relapse may occur, how long it may last, its likely severity and which bodily systems it may affect. However, the broad impact of relapses on HRQL has little weight in economic models. Consideration is needed of how best to incorporate the effects of relapses in cost-effectiveness analyses in a manner that reflects their salience to people with MS [77] . For example, qualitative research could begin to explore the impact of fear of relapse on HRQL during remission and how this might be represented in QALY weights.
The key finding of this review is the need for current, longitudinal, prospective cohort studies of people with MS, which collect data on outcomes and costs associated with MS. Contemporaneous MS natural history data are long overdue. The ongoing reliance on cohort data from 30 years hence limits the evaluative framework, particularly given advances during the last decade in the care and treatment of MS. Data from people with all sub-types of MS are needed, and efforts should be made to ensure representative samples by careful consideration of the sampling techniques used for recruitment (so that initial uptake is high) and the response methods used for data collection (so that retention over time is maintained). The findings from such research need to be generalisable to broad populations of people with MS in order to provide valid and reliable estimates of resource use, cost and health-related quality of life that, in turn, can be used in cost-effectiveness analyses. Initiatives in the UK offer promise, with the establishment of a UK Register of people with MS, which aims to recruit a representative sample. Data collection began in May 2011 and, in the first 3 months over 7,000 individuals were enrolled [85] . In addition, the South West Impact of MS project is currently collecting detailed resource and health outcome data over multiple time points [76] .
Current approaches to estimating the value of treatments for MS are limited and are often contentious. Weaknesses with the current CEA framework for assessing treatments for MS are recognised and have led to calls for improvements in methods, such that recent guidance from NICE [14] has called for the development of a new economic model. Until this is achieved, and particularly in the context of the on-going controversy surrounding the cost effectiveness of DMDs, decision makers need to understand the limitations of the data that are currently being used in economic models and the potential impact of this on model findings.
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